AIM-HIGH Coordinating Center
Axio Research
2601 Fourth Ave. Suite 200
Seattle, WA 98121

Bibliography (January 2014)

Published Manuscripts

1. The AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. Am Heart J 2011;161(3):471.e2-477.e2.
2. The AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. Am Heart J 2011;161:538-43.
3. The AIM-HIGH Investigators. Nicain in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med 2011; 365:2255-2267
4. Boden, WE, Probstfield, JL. Interpreting the AIM-HIGH Trial Results: Insights and Implications for Clinical Practice. CardioSource. Januray 3, 2012.
5. Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM. Relationship of Apolipoproteins A-1 and B, and Lipoprotein (a) to Cardiovascular Outcomes in the AIM-HIGH Trial. J Am Coll Cardiol. 2013 Aug 7. doi:pii: S0735-1097(13)03076-3. 10.1016/j.jacc.2013.06.051. [Epub ahead of print] PubMed PMID: 23973688.
6. Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE. Relationship of Lipoproteins to Cardiovascular Events in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) Trial. J Am Coll Cardiol. 2013 Jul 20. doi:pii: S0735 1097(13)02835-0. 10.1016/j.jacc.2013.07.023. [Epub ahead of print] PubMed PMID: 23916935.
7. Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub, WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE on behalf of the AIM-HIGH Investigators. Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients with Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Griglycerides: Impace on Global Health Outcome (AIM-HIGH) Trial. *Stroke.* 2013;44:2688-2693; originally published online July 23, 2013

Abstracts

1. The AIM-HIGH Investigators. Extended-Release Niacin Does not Reduce Clinical Events in Patients with Established Cardiovascular Disease Whose LDL-Cholesterol is Optimally Controlled with Statin Therapy: Results from the AIM-HIGH Trial. American Heart Association Scientific Sessions, November 2011. 2011-LBCT-18623-AHA

AIM HIGH is sponsored by the National Heart, Lung, and Blood Institute
with additional support from AbbVie, Inc

2. Koon Teo, McMaster; Larry Goldstein; Bernard Chaitman; Shannon Grant; William S. Weintraub; David C. Anderson; Cathy A. Sil; Salvador Cruz-Flores; Robert J. Padley; William J. Kostuk; Todd J. Anderson; William E. Boden. No Independent Association between Extended-Release Niacin (ERN) Therapy and Ischemic Stroke in Patients with Established Cardiovascular Disease: A Detailed Analysis from the AIM HIGH Trial. International Stroke Conference, February 2013 13-ISC-A-4059-AHA
3. The AIM-HIGH Investigators. Comparison of Extended-Release Niacin vs. Placebo in Statin-Treated Patients with Low Baseline Levels of HDL-C and Well-Controlled ON-Treatment LDL-C: Extended One-Year Follow-up Outcomes from AIM-HIGH. American Heart Association Scientific Sessions, November 2013 (poster).
4. Boden WE, Robinson JG, Miller M, Simmons D, Xu P, Abramson B, Elam MB, Nash SD, Brown TM, Fleg JL, Desvignes-Nickens P. Does the Metabolic Syndrome Cluster Provide Incremental Prognostic Information over the Individual Risk Factor Components? American Heart Association Scientific Sessions, November 2013.
5. Kevin D. O'Brien, Suzanne Peck, Huijin Chen, Moni Neralidek, Maria de Gador Canton, Daniel Isquith, Nayak Polissar, Chris Geohas, David Hinchman, Xue Qiao Zhao, Jeffrey Probstfield, William Kerwin. An MRI Derived Marker of Carotid Plaque Inflammation Decreases With Lipid Lowering Therapy: Results From the AIM-HIGH Trial. American Heart Association Scientific Sessions, November 2013 (poster).
6. The AIM-HIGH MRI Substudy Investigators. Clinical Factors Associated with High-Risk Plaque Features by MRI in AIM-HIGH: Baseline Report of the AIM-HIGH Carotid MRI Sub-study. American Heart Association Scientific Sessions, November 2013.
7. Kevin D. O'Brien, Daniel S. Hippe, Huijun Chen, Moni Neradilek, Jeffrey L. Probstfield, Suzanne Peck, Gador Canton, Chun Yuan, Nayak Polissar, Xue-Qiao Zhao, William S. Kerwin. Clinical variables correlated with MRI-assessed carotid plaque neovasculature in statin-treated patients. American Heart Association Scientific Sessions, November 2013 (poster).
8. Sony Tuteja, Liming Qu, Mingyao Li, Richard Dunbar, Megan Mucksavage, Stephanie DerOhannessian, Muredach Reilly, Daniel Rader. Diacylglycerol kinase β (DGKB) genotype predicts response to niacin induced flushing and changes in insulin in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) trial. American Heart Association Scientific Sessions, November 2013 (poster).
9. Koon Teo, Larry B Goldstein, Bernard R Chaitman, Shannon Grant, William S Weintraub, David C Anderson, Cathy A Sila, Salvador Cruz-Flores, Robert J Padley, William J Kostuk, Todd J Anderson, William E Boden. No Independent Association Between Extended-Release Niacin Therapy and Ischemic Strokes in Patients with Established Cardiovascular Disease: A Detailed Analysis from the AIM-HIGH Trial. American Heart Association Scientific Sessions, November 2013 (poster).